GlassScriptPhysician profile
Melinda A Frame
NPI 1548581523
$15,720.60
in general payments reported to CMS, 2019-2025
34 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $555 · 2021: $299 · 2022: $146 · 2023: $180 · 2024: $272 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $2,999 · Food and Beverage: $1,460 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,080.00 |
| Travel and Lodging | $2,998.76 |
| Food and Beverage | $1,460.24 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtual Incision Corporation | $10,245.57 | 2025 | Mira |
| Biogen, INC. | $2,080.00 | 2025 | Zurzuvae |
| Medical Device Business Services, INC. | $1,189.12 | 2025 | Harmonic |
| Intuitive Surgical, INC. | $520.78 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $234.85 | 2023-2025 | |
| Daiichi Sankyo INC. | $166.98 | 2024-2025 | Injectafer |
| Ethicon US, LLC | $147.26 | 2019-2025 | Enseal, Harmonic, Echelon Flex |
| Abbvie INC. | $133.42 | 2019-2023 | |
| Aspira Women'S Health INC | $128.28 | 2021 | |
| Pfizer INC. | $103.18 | 2019-2023 | |
| Coopersurgical, INC. | $90.03 | 2019-2023 | Mara Console |
| Bayer Healthcare Pharmaceuticals INC. | $73.33 | 2019-2025 | |
| Exeltis, USA INC. | $67.83 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $61.49 | 2023-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $54.73 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.81 | 2021-2025 | Veozah |
| Organon LLC | $40.15 | 2022-2025 | Jada System |
| Lupin INC. | $36.79 | 2019-2021 | |
| Eisai INC. | $34.08 | 2020 | |
| Sage Therapeutics, LLC | $33.34 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $28.63 | 2022-2023 | Myosure Tissue Removal Device |
| Meditrina | $25.93 | 2023-2025 | |
| Shield Therapeutics INC | $24.85 | 2024 | |
| Zyla Life Sciences, INC. | $17.46 | 2020 | |
| Urovant Sciences INC | $16.57 | 2022 | |
| Millicent US INC | $16.33 | 2025 | Femlyv, Intrarosa |
| Becton, Dickinson and Company | $14.77 | 2023 | Bd Onclarity |
| Pacira Pharmaceuticals Incorporated | $14.68 | 2021 | |
| Amgen INC. | $13.89 | 2021 | |
| Avion Pharmaceuticals | $13.21 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2019 | |
| Smith+Nephew, INC. | $12.79 | 2021 | |
| Myovant Sciences INC. | $12.24 | 2021 | |
| Evofem Biosciences, INC. | $11.15 | 2025 | Solosec, Phexx, Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Frame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.